RxDoctor Payments Data

Alban Bacchus, MD

Internal Medicine · Palm Springs, FLNPI 1710176474

Payments from drug & device makers

$2,088in general payments, 2019–2025

Across 91 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$668
  • Exact Sciences$360
  • Idorsia Pharmaceuticals US Inc$177
  • Pfizer$154
  • Shionogi Inc$128
  • Biohaven Pharmaceuticals, Inc.$107
  • plus $495 from 12 others

What the payments were for

  • Food & beverage$1,960100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,088 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$104,074
Medicare patients
146
Services billed
1,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$30,438
XareltoRivaroxaban24$28,255
FarxigaDapagliflozin Propanediol17$23,789
JanuviaSitagliptin Phosphate12$19,019
EliquisApixaban21$17,221
JardianceEmpagliflozin11$14,984
Atorvastatin Calcium332$2,170
Nebivolol Hcl17$1,888
Omeprazole125$1,662
PaxlovidNirmatrelvir/Ritonavir11$1,429
Rosuvastatin Calcium161$1,270
Amlodipine Besylate271$1,215
Levothyroxine Sodium111$1,112
Metformin Hcl164$1,096
Nifedipine ErNifedipine37$1,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$87$30,43826 claims
Johnson & JohnsonXarelto$21$28,25524 claims
PfizerEliquis, Paxlovid$154$18,65032 claims
AbbVieSynthroid$668$1,06428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Palm Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →